HCW Biologics regains full ex vivo rights to HCW9206, HCW9201 from Wugen

HCW Biologics

HCW Biologics

HCWB

0.00
  • HCW Biologics exercised an option to regain full ex vivo rights to HCW9206 and HCW9201 from Wugen.
  • Transaction carried no cost to HCW; it kept a nonrefundable upfront fee that included 2,200,000 Wugen common shares.
  • Move repositions the company to commercialize the reagents for CAR-T and NK-cell therapy manufacturing through partners.
  • HCW cited published data indicating HCW9206 could improve CAR-T manufacturing efficiency, enrich T-memory stem cells, reduce costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270745PRIMZONEFULLFEED9727085) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.